Drugs (Prices Control) Order (DPCO): Key Provisions and Price-Control Mechanisms in India
The Drugs (Prices Control) Order (DPCO) provides the framework for regulating prices of medicines in India. It seeks to balance access to essential medicines with oversight of pharmaceutical pricing, while assigning implementation and monitoring responsibilities to the National Pharmaceutical Pricing Authority (NPPA).
Legal Framework and Evolution
- Statutory basis: The DPCO is issued under Section 3 of the Essential Commodities Act, 1955, which empowers the Central Government to regulate the production, supply, distribution, trade and commerce of essential commodities, including drugs.
- Evolution: Drug price-control orders have been issued since 1962. Important earlier orders include those of 1979, 1987 and 1995. The current comprehensive framework is the Drugs (Prices Control) Order, 2013.
- Purpose: Price regulation seeks to support the availability of essential medicines at reasonable prices, prevent profiteering and promote stability in the pharmaceutical market.
DPCO 2013: Scope and Core Provisions
The DPCO 2013 distinguishes between scheduled and non-scheduled formulations. Scheduled formulations are listed in its First Schedule, which corresponds to the National List of Essential Medicines (NLEM). Their prices are subject to government control.
- Scheduled formulations: The government fixes a ceiling price for a specified formulation, strength and dosage form. A manufacturer cannot sell a scheduled formulation above the ceiling price, apart from applicable local taxes.
- Non-scheduled formulations: Their prices are not directly fixed through ceiling prices under the DPCO. However, a manufacturer cannot increase the maximum retail price (MRP) by more than 10% during the preceding 12 months.
- Retail price limit: Retailers cannot charge more than the MRP declared by the manufacturer or importer.
- Monitoring and enforcement: The NPPA monitors prices of scheduled and non-scheduled formulations. The DPCO provides for recovery, with interest, of amounts overcharged in contravention of its provisions.
The link to the NLEM focuses price control on medicines identified as essential. The framework therefore combines direct price limits for scheduled medicines with restrictions on annual increases for other formulations. These measures concern both consumer protection and the regulation of the medicines market.
Price-Control Mechanisms
- Market-based ceiling price: For a scheduled formulation, the ceiling price is based on the simple average of the market prices of brands with a market share of at least 1% of the total market turnover for that drug.
- Application of the ceiling: The fixed ceiling applies to the specified strength and dosage form. Manufacturers must keep the selling price within the applicable limit, subject to local taxes.
- Annual increase cap: For non-scheduled formulations, manufacturers may set prices, but annual MRP increases cannot exceed 10% of the MRP during the preceding 12 months.
- Medical devices: Medical devices may be brought within the price-control framework when notified as “drugs” under the Drugs and Cosmetics Act, 1940. This enables the NPPA to fix ceiling prices for them.
The DPCO’s market-based approach uses prevailing market prices to set limits for scheduled formulations, while the annual cap constrains increases for non-scheduled products. These controls aim to improve affordability without treating every formulation as subject to the same pricing mechanism.
National Pharmaceutical Pricing Authority
The NPPA was established on 29 August 1997 as an attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It is responsible for implementing the DPCO and carries out functions under powers delegated by the Central Government.
- Price regulation: Fixes and revises ceiling prices for scheduled formulations and monitors prices of non-scheduled formulations.
- Availability: Monitors the availability of medicines, identifies shortages and takes remedial steps to support adequate supply.
- Market information: Maintains data on production, exports, imports, company market shares and profitability for bulk drugs and formulations.
- Overcharge recovery: Takes steps to recover amounts charged above the permitted prices for controlled drugs.
- Advice and studies: Undertakes studies on drug pricing and availability and advises the Central Government on related matters.
Key Prelims Takeaways
- Legal basis: The DPCO operates under the Essential Commodities Act, 1955.
- Current order: The applicable comprehensive order is the DPCO 2013.
- Scheduled medicines: The First Schedule corresponds to the NLEM and identifies formulations subject to ceiling prices.
- Ceiling-price method: Scheduled-formulation prices use a simple average of market prices for brands with at least 1% market share.
- Non-scheduled medicines: Annual MRP increases are capped at 10% over the preceding 12 months.
- Regulator: The NPPA, established in 1997 under the Department of Pharmaceuticals, implements the DPCO and monitors prices and availability.
Recent Context
On 13 November 2026, the Ministry of Chemicals and Fertilizers extended the ceiling prices for orthopaedic knee implants until 15 January 2027. The prices were first notified on 16 August 2017; provisions and notes (b) to (t) of that notification remain in force. In September 2026, manufacturers and importers were directed to submit data through the IPDMS 2.0 Portal.